vs
爱德华生命科学（EW）与Masco（MAS）财务数据对比。点击上方公司名可切换其他公司
Masco的季度营收约是爱德华生命科学的1.2倍（$1.9B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 11.9%，领先11.2%），爱德华生命科学同比增速更快（16.7% vs 6.5%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -4.2%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
美国家居建材企业Masco主营家装及新建住宅市场相关产品，旗下拥有20余家子公司，在全球运营近80座生产工厂，其中美国本土近60座，海外地区超20座。公司1969年于纽交所挂牌上市，后实现快速增长，成功跻身美国财富500强榜单。
EW vs MAS — 直观对比
营收规模更大
MAS
是对方的1.2倍
$1.6B
营收增速更快
EW
高出10.2%
6.5%
净利率更高
EW
高出11.2%
11.9%
两年增速更快
EW
近两年复合增速
-4.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $1.9B |
| 净利润 | $380.7M | $228.0M |
| 毛利率 | 78.0% | 35.8% |
| 营业利润率 | 1.8% | 16.5% |
| 净利率 | 23.1% | 11.9% |
| 营收同比 | 16.7% | 6.5% |
| 净利润同比 | 6.8% | 14.5% |
| 每股收益（稀释后） | $0.66 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWMAS
| Q1 26 | $1.6B | $1.9B | ||
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.6B | $1.9B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $1.4B | $1.8B | ||
| Q4 24 | $1.4B | $1.8B | ||
| Q3 24 | $1.4B | $2.0B | ||
| Q2 24 | $1.4B | $2.1B |
净利润EWMAS
| Q1 26 | $380.7M | $228.0M | ||
| Q4 25 | $91.2M | $165.0M | ||
| Q3 25 | $291.1M | $189.0M | ||
| Q2 25 | $333.2M | $270.0M | ||
| Q1 25 | $358.0M | $186.0M | ||
| Q4 24 | $385.6M | $182.0M | ||
| Q3 24 | $3.1B | $167.0M | ||
| Q2 24 | $366.3M | $258.0M |
毛利率EWMAS
| Q1 26 | 78.0% | 35.8% | ||
| Q4 25 | 78.1% | 33.9% | ||
| Q3 25 | 77.8% | 34.2% | ||
| Q2 25 | 77.5% | 37.6% | ||
| Q1 25 | 78.7% | 35.8% | ||
| Q4 24 | 78.9% | 34.8% | ||
| Q3 24 | 80.6% | 36.6% | ||
| Q2 24 | 79.9% | 37.5% |
营业利润率EWMAS
| Q1 26 | 1.8% | 16.5% | ||
| Q4 25 | 9.6% | 13.8% | ||
| Q3 25 | 19.8% | 15.8% | ||
| Q2 25 | 26.8% | 20.1% | ||
| Q1 25 | 27.9% | 15.9% | ||
| Q4 24 | 22.6% | 15.9% | ||
| Q3 24 | 25.9% | 18.0% | ||
| Q2 24 | 26.8% | 19.0% |
净利率EWMAS
| Q1 26 | 23.1% | 11.9% | ||
| Q4 25 | 5.8% | 9.2% | ||
| Q3 25 | 18.7% | 9.9% | ||
| Q2 25 | 21.7% | 13.2% | ||
| Q1 25 | 25.3% | 10.3% | ||
| Q4 24 | 27.8% | 10.0% | ||
| Q3 24 | 226.7% | 8.4% | ||
| Q2 24 | 26.7% | 12.3% |
每股收益（稀释后）EWMAS
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $0.81 | ||
| Q3 25 | $0.50 | $0.90 | ||
| Q2 25 | $0.56 | $1.28 | ||
| Q1 25 | $0.61 | $0.87 | ||
| Q4 24 | $0.65 | $0.85 | ||
| Q3 24 | $5.13 | $0.77 | ||
| Q2 24 | $0.61 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | $2.9B |
| 股东权益账面价值 | — | $27.0M |
| 总资产 | — | $5.2B |
| 负债/权益比越低杠杆越低 | — | 109.07× |
8季度趋势，按日历期对齐
现金及短期投资EWMAS
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $647.0M | ||
| Q3 25 | $3.8B | $559.0M | ||
| Q2 25 | $4.1B | $390.0M | ||
| Q1 25 | $3.9B | $377.0M | ||
| Q4 24 | $4.0B | $634.0M | ||
| Q3 24 | $4.4B | $646.0M | ||
| Q2 24 | $2.0B | $398.0M |
总债务EWMAS
| Q1 26 | — | $2.9B | ||
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EWMAS
| Q1 26 | — | $27.0M | ||
| Q4 25 | $10.3B | $-185.0M | ||
| Q3 25 | $10.2B | $-78.0M | ||
| Q2 25 | $10.5B | $-84.0M | ||
| Q1 25 | $10.1B | $-254.0M | ||
| Q4 24 | $10.0B | $-279.0M | ||
| Q3 24 | $9.5B | $-88.0M | ||
| Q2 24 | $7.4B | $-26.0M |
总资产EWMAS
| Q1 26 | — | $5.2B | ||
| Q4 25 | $13.7B | $5.2B | ||
| Q3 25 | $13.3B | $5.3B | ||
| Q2 25 | $13.5B | $5.3B | ||
| Q1 25 | $13.0B | $5.1B | ||
| Q4 24 | $13.1B | $5.0B | ||
| Q3 24 | $13.0B | $5.3B | ||
| Q2 24 | $10.1B | $5.4B |
负债/权益比EWMAS
| Q1 26 | — | 109.07× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
